<p align="center" style="margin-bottom: 0cm; line-height: 100%"><span style="text-transform: uppercase"><b>Critérios
de classificação/ diagnóstico, diretrizes (“Guidelines”),
Recomendações E MÉTRICAS </b></span>
</p>
<p align="center" style="margin-bottom: 0cm; line-height: 100%"><span style="text-transform: uppercase"><b>em
Reumatologia</b></span></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">Para controle
interno:</p>
<table width="707" cellpadding="7" cellspacing="0">
	<col width="370">
	<col width="90">
	<col width="203">
	<tr valign="top">
		<td width="370" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p><br/>

			</p>
		</td>
		<td width="90" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p>Última revisão</p>
		</td>
		<td width="203" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p>Pendências</p>
		</td>
	</tr>
	<tr valign="top">
		<td width="370" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p style="margin-bottom: 0cm"><b>(SBR) Sociedade Brasileira de
			Reumatologia</b></p>
			<p style="margin-bottom: 0cm">http://www.reumatologia.com.br/</p>
			<p><br/>

			</p>
		</td>
		<td width="90" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p>Mar/16</p>
		</td>
		<td width="203" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p>Chequei RBR até 2010. Falta 2009 para trás</p>
		</td>
	</tr>
	<tr valign="top">
		<td width="370" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p style="margin-bottom: 0cm"><span lang="en-US"><b>(ACR) American
			College of Rheumatology</b></span></p>
			<p style="margin-bottom: 0cm"><span lang="en-US">http://www.rheumatology.org/</span></p>
			<p lang="en-US"><br/>

			</p>
		</td>
		<td width="90" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p><span lang="en-US">Mar/16</span></p>
		</td>
		<td width="203" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p><span lang="en-US">Nenhuma.</span></p>
		</td>
	</tr>
	<tr valign="top">
		<td width="370" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p style="margin-bottom: 0cm"><span lang="en-US"><b>(EULAR)
			European League Against Rheumatism</b></span></p>
			<p style="margin-bottom: 0cm"><span lang="en-US">http://www.eular.org/</span></p>
			<p lang="en-US"><br/>

			</p>
		</td>
		<td width="90" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p><span lang="en-US">Mar/16</span></p>
		</td>
		<td width="203" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p><span lang="en-US">Nenhuma.</span></p>
		</td>
	</tr>
	<tr valign="top">
		<td width="370" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p style="margin-bottom: 0cm"><b>(ASAS) Sociedade Internacional
			para Avaliação das Espondiloartropatias</b></p>
			<p style="margin-bottom: 0cm">http://www.asas-group.org/mission-statement.php</p>
			<p><br/>

			</p>
		</td>
		<td width="90" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p>Mar/16</p>
		</td>
		<td width="203" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p><br/>

			</p>
		</td>
	</tr>
	<tr valign="top">
		<td width="370" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p style="margin-bottom: 0cm"><b>(SBC) Sociedade Brasileira de
			Cardiologia</b></p>
			<p style="margin-bottom: 0cm">http://www.cardiol.br/</p>
			<p><br/>

			</p>
		</td>
		<td width="90" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p>Mar/16</p>
		</td>
		<td width="203" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p><br/>

			</p>
		</td>
	</tr>
	<tr valign="top">
		<td width="370" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p style="margin-bottom: 0cm"><b>(SBDens) Sociedade Brasileira de
			Densitometria Clínica</b></p>
			<p style="margin-bottom: 0cm">http://www.sbdens.org.br/index.php</p>
			<p><br/>

			</p>
		</td>
		<td width="90" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p>Mai/16</p>
		</td>
		<td width="203" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p><br/>

			</p>
		</td>
	</tr>
	<tr valign="top">
		<td width="370" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p style="margin-bottom: 0cm"><b>(NOF) National Osteoporosis
			Foundation</b></p>
			<p style="margin-bottom: 0cm">https://www.nof.org/</p>
			<p><br/>

			</p>
		</td>
		<td width="90" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p><br/>

			</p>
		</td>
		<td width="203" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p><br/>

			</p>
		</td>
	</tr>
	<tr valign="top">
		<td width="370" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p style="margin-bottom: 0cm"><span lang="en-US"><b>(ISCD) The
			International Society for Clinical Densitometry</b></span></p>
			<p style="margin-bottom: 0cm"><span lang="en-US">http://www.iscd.org/</span></p>
			<p lang="en-US"><a name="_GoBack"></a><br/>

			</p>
		</td>
		<td width="90" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p lang="en-US"><br/>

			</p>
		</td>
		<td width="203" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p lang="en-US"><br/>

			</p>
		</td>
	</tr>
	<tr valign="top">
		<td width="370" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p lang="en-US"><br/>

			</p>
		</td>
		<td width="90" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p lang="en-US"><br/>

			</p>
		</td>
		<td width="203" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p lang="en-US"><br/>

			</p>
		</td>
	</tr>
	<tr valign="top">
		<td width="370" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p lang="en-US"><br/>

			</p>
		</td>
		<td width="90" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p lang="en-US"><br/>

			</p>
		</td>
		<td width="203" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p lang="en-US"><br/>

			</p>
		</td>
	</tr>
	<tr valign="top">
		<td width="370" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p lang="en-US"><br/>

			</p>
		</td>
		<td width="90" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p lang="en-US"><br/>

			</p>
		</td>
		<td width="203" style="border: 1px dotted #00000a; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0.2cm; padding-right: 0.19cm">
			<p lang="en-US"><br/>

			</p>
		</td>
	</tr>
</table>
<p lang="en-US" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p lang="en-US" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p lang="en-US" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p lang="en-US" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p lang="en-US" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p lang="en-US" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p lang="en-US" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p lang="en-US" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p lang="en-US" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p lang="en-US" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p lang="en-US" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p lang="en-US" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p lang="en-US" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%; page-break-before: always">
<b>CRITÉRIOS DE CLASSIFICAÇÃO E DE DIAGNÓSTICO DAS DOENÇAS
REUMATOLÓGICAS</b></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Artrite
idiopática juvenil (AIJ)</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2016) (ACR/ EULAR)
Síndrome de ativação macrofágica na AIJ sistêmica</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/A-and-R-Classification-Criteria-Macrophage-Activation-Syndrome-2016.pdf">http://www.rheumatology.org/Portals/0/Files/A-and-R-Classification-Criteria-Macrophage-Activation-Syndrome-2016.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Artrite
reumatoide</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2013) (EULAR)
Definição de artrite erosiva para ser aplicada nos critérios 2010
ACR/EULAR</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/early/2013/02/01/annrheumdis-2012-202779.abstract?papetoc">http://ard.bmj.com/content/early/2013/02/01/annrheumdis-2012-202779.abstract?papetoc</a></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2010) (ACR/ EULAR) 
</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/2010_revised_criteria_classification_ra.pdf">http://www.rheumatology.org/Portals/0/Files/2010_revised_criteria_classification_ra.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2010) (ACR/ EULAR)
– Resumo</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/2010%20Rheumatoid%20Arthritis%20Classification_EXCERPT%202010.pdf">http://www.rheumatology.org/Portals/0/Files/2010%20Rheumatoid%20Arthritis%20Classification_EXCERPT%202010.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%">(1987) (ACR) 
</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/1987_revised_criteria_classification_ra.pdf">http://www.rheumatology.org/Portals/0/Files/1987_revised_criteria_classification_ra.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%">(1987) (ACR) –
Resumo</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/1987%20Rheumatoid%20Arthritis%20Classification_Excerpt%201987.pdf">http://www.rheumatology.org/Portals/0/Files/1987%20Rheumatoid%20Arthritis%20Classification_Excerpt%201987.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Esclerose
Sistêmica</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2013) (ACR/ EULAR)</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/2013%20ACR%20EULAR%20SSc%20Classification%20Criteria_Complete%20article.pdf">http://www.rheumatology.org/Portals/0/Files/2013%20ACR%20EULAR%20SSc%20Classification%20Criteria_Complete%20article.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%">(1980) (ACR)</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/Systemic%20Sclerosis%201980.pdf">http://www.rheumatology.org/Portals/0/Files/Systemic%20Sclerosis%201980.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Fibromialgia</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2010) (ACR)</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/2010_Preliminary_Diagnostic_Criteria.pdf">http://www.rheumatology.org/Portals/0/Files/2010_Preliminary_Diagnostic_Criteria.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2010) (ACR) -
Resumo</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/2010%20Fibromyalgia%20Diagnostic%20Criteria_Excerpt.pdf">http://www.rheumatology.org/Portals/0/Files/2010%20Fibromyalgia%20Diagnostic%20Criteria_Excerpt.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(1990) (ACR)</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/1990_Criteria_for_Classification_Fibro.pdf">http://www.rheumatology.org/Portals/0/Files/1990_Criteria_for_Classification_Fibro.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%">(1990) (ACR) -
Resumo</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/1990%20Fibromyalgia_Excerpt.pdf">http://www.rheumatology.org/Portals/0/Files/1990%20Fibromyalgia_Excerpt.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Gota</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2015) (ACR/ EULAR) 
</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/2015%20Gout%20Classification%20criteria.pdf">http://www.rheumatology.org/Portals/0/Files/2015%20Gout%20Classification%20criteria.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2015) (ACR/ EULAR)
– Suplemento: critérios prévios</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/Supplementary_Table_1.ACR-EULAR_gout_classification.pdf">http://www.rheumatology.org/Portals/0/Files/Supplementary_Table_1.ACR-EULAR_gout_classification.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2015) (ACR/ EULAR)
– Calculadora</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://goutclassificationcalculator.auckland.ac.nz/">http://goutclassificationcalculator.auckland.ac.nz/</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Lúpus
Eritematoso Sistêmico</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(1997) (ACR) –
Revisão dos critérios de 1982</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/1997%20Update%20of%201982%20Revised.pdf">http://www.rheumatology.org/Portals/0/Files/1997%20Update%20of%201982%20Revised.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%">(1982) (ACR) –
Resumo</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/1982%20SLE%20Classification_Excerpt.pdf">http://www.rheumatology.org/Portals/0/Files/1982%20SLE%20Classification_Excerpt.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Osteoartrite</b></p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>(1990) (ACR) Mão</b></p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/1990_classification_%20oa_hand.pdf">http://www.rheumatology.org/Portals/0/Files/1990_classification_%20oa_hand.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>(1990) (ACR) Mão
- Resumo</b></p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/Osteoarthritis%20of%20the%20Hand%201990_Excerpt.pdf">http://www.rheumatology.org/Portals/0/Files/Osteoarthritis%20of%20the%20Hand%201990_Excerpt.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>(1991) (ACR)
Quadril</b></p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/1991_classification_oa_hip.pdf">http://www.rheumatology.org/Portals/0/Files/1991_classification_oa_hip.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>(1991) (ACR)
Quadril – Resumo</b></p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/1991%20Osteoarthritis%20of%20the%20Hip_Excerpt.pdf">http://www.rheumatology.org/Portals/0/Files/1991%20Osteoarthritis%20of%20the%20Hip_Excerpt.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"> <b>(1986) (ACR)
Joelho</b></p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/Complete%20Article_Osteoarthritis%20of%20the%20Knee%20-%201986.pdf">http://www.rheumatology.org/Portals/0/Files/Complete%20Article_Osteoarthritis%20of%20the%20Knee%20-%201986.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>(1986) (ACR)
Joelho – Resumo</b></p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/Idiopathic%20OA%20of%20the%20Knee.pdf">http://www.rheumatology.org/Portals/0/Files/Idiopathic%20OA%20of%20the%20Knee.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Polimialgia
reumática</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2012) (ACR/ EULAR) 
</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/PMR%20Class%20Criteria%20paper.pdf">http://www.rheumatology.org/Portals/0/Files/PMR%20Class%20Criteria%20paper.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Síndrome de
Sjögren</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2012) (ACR)</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/2012%20ACR%20Sjogrens%20Classification%20Criteria%20v.pdf">http://www.rheumatology.org/Portals/0/Files/2012%20ACR%20Sjogrens%20Classification%20Criteria%20v.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Vasculites</b></p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>(2010) (EULAR)
Critérios EULAR/PRINTO/PRES para púrpura de Henoch-Schönlein,
poliarterite nodosa infantil, granulomatose com poliangeíte infantil
e arterite de Takayasu infantil. Ankara 2008, critérios de
classificação finais</b></p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/69/5/798.abstract?sid=60bd2b84-745b-4728-a9d8-e6a8c679c32b">http://ard.bmj.com/content/69/5/798.abstract?sid=60bd2b84-745b-4728-a9d8-e6a8c679c32b</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>(1990) (ACR)
Arterite de células gigantes (Arterite temporal) </b>
</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/Giant%20Cell%20(Temporal)%20Arteritis%20-%201990_Completed%20Article.pdf">http://www.rheumatology.org/Portals/0/Files/Giant%20Cell%20(Temporal)%20Arteritis%20-%201990_Completed%20Article.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>(1990) (ACR)
Arterite de células gigantes (Arterite temporal)  - Resumo</b></p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/Giant%20Cell%20Arteritis_Excerpt.pdf">http://www.rheumatology.org/Portals/0/Files/Giant%20Cell%20Arteritis_Excerpt.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>(1990) (ACR)
Arterite de Takayasu</b></p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/1990%20CRITERIA%20FOR%20THE%20CLASSIFICATION%20OF%20TAKAYASU%20ARTERITIS_Complete%20Article.pdf">http://www.rheumatology.org/Portals/0/Files/1990%20CRITERIA%20FOR%20THE%20CLASSIFICATION%20OF%20TAKAYASU%20ARTERITIS_Complete%20Article.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>(1990) (ACR)
Arterite de Takayasu – Resumo</b></p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/Takayasu%20Arteritis_Excerpt.pdf">http://www.rheumatology.org/Portals/0/Files/Takayasu%20Arteritis_Excerpt.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>(1990) (ACR)
Granulomatose com Poliangeite (Granulomatose de Wegener)</b></p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/1990%20criteria%20for%20the%20classification%20of%20Wegener's%20granulomatosis_Complete%20Article.pdf">http://www.rheumatology.org/Portals/0/Files/1990%20criteria%20for%20the%20classification%20of%20Wegener's%20granulomatosis_Complete%20Article.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>(1990) (ACR)
Granulomatose com Poliangeite (Granulomatose de Wegener)</b></p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/Wegener_Excerpt.pdf">http://www.rheumatology.org/Portals/0/Files/Wegener_Excerpt.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>(1990) (ACR)
Granulomatose eosinofílica com poliangeite (Síndrome de
Churg-Strauss) </b>
</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/1990%20criteria%20for%20the%20classification%20of%20Churg-Strauss%20syndrome.pdf">http://www.rheumatology.org/Portals/0/Files/1990%20criteria%20for%20the%20classification%20of%20Churg-Strauss%20syndrome.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>(1990) (ACR)
Granulomatose eosinofílica com poliangeite (Síndrome de
Churg-Strauss) - Resumo
</b><a href="http://www.rheumatology.org/Portals/0/Files/Churg%201990_Excerpt.pdf">http://www.rheumatology.org/Portals/0/Files/Churg%201990_Excerpt.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>(1990) (ACR)
Poliarterite nodosa – Resumo</b></p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/1990%20Criteria%20for%20the%20Classification%20of%20Polyarteritis%20Nodosa_Excerpt.pdf">http://www.rheumatology.org/Portals/0/Files/1990%20Criteria%20for%20the%20Classification%20of%20Polyarteritis%20Nodosa_Excerpt.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>(1990) (ACR)
Púrpura de Henoch-Schönlein</b></p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/1990%20criteria%20for%20the%20classification%20of%20Henoch-Sch%C3%B6nlein%20purpura_Complete%20Article.pdf">http://www.rheumatology.org/Portals/0/Files/1990%20criteria%20for%20the%20classification%20of%20Henoch-Sch%C3%B6nlein%20purpura_Complete%20Article.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>(1990) (ACR)
Vasculite por hipersensibilidade</b></p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/1990%20criteria%20for%20the%20classification%20of%20hypersensitivity%20vasculitis_Complete%20Article.pdf">http://www.rheumatology.org/Portals/0/Files/1990%20criteria%20for%20the%20classification%20of%20hypersensitivity%20vasculitis_Complete%20Article.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>(1990) (ACR)
Vasculite por hipersensibilidade – Resumo</b></p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/Critieria%20for%20Hypersensitivity%20Vasculitis%201990_Tree%20Format.pdf">http://www.rheumatology.org/Portals/0/Files/Critieria%20for%20Hypersensitivity%20Vasculitis%201990_Tree%20Format.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0.35cm; line-height: 115%"><br/>
<br/>

</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%; page-break-before: always">
<b>DIRETRIZES OU RECOMENDAÇÕES QUANTO À AVALIAÇÃO, MANEJO E
TRATAMENTO DAS DOENÇAS REUMATOLÓGICAS</b></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Artrite
Idiopática Juvenil (AIJ)</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2015) (EULAR)
Considerações EULAR-PReS sobre exames de imagem no diagnóstico e
manejo de artrite idiopática juvenil na prática clínica</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/early/2015/08/05/annrheumdis-2015-207892?papetoc">http://ard.bmj.com/content/early/2015/08/05/annrheumdis-2015-207892?papetoc</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2013) (ACR)
Atualização da recomendação de 2011 sobre o tratamento da AIJ</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/2013%20Update%20of%20the%202011%20ACR%20Recommendations%20for%20the%20Treatment%20of%20Juvenile%20Idiopathic%20Arthritis.pdf">http://www.rheumatology.org/Portals/0/Files/2013%20Update%20of%20the%202011%20ACR%20Recommendations%20for%20the%20Treatment%20of%20Juvenile%20Idiopathic%20Arthritis.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2011) (ACR)
Recomendação sobre o tratamento da AIJ</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/2011%20ACR%20Recommendations%20for%20the%20Treatment%20of%20Juvenile%20Idiopathic%20Arthritis.pdf">http://www.rheumatology.org/Portals/0/Files/2011%20ACR%20Recommendations%20for%20the%20Treatment%20of%20Juvenile%20Idiopathic%20Arthritis.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2011) (ACR) Guia
clínico para tratamento da AIJ (Resumo)</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/ACR%202011%20Juvenile%20Idiopathic%20Arthritis%20Clinicians%20Guide.pdf">http://www.rheumatology.org/Portals/0/Files/ACR%202011%20Juvenile%20Idiopathic%20Arthritis%20Clinicians%20Guide.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(1997) (ACR)
Critérios de melhora na AIJ</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/Preliminary%20Definition%20of%20Improvement%20in%20Juvenile%20RA.pdf">http://www.rheumatology.org/Portals/0/Files/Preliminary%20Definition%20of%20Improvement%20in%20Juvenile%20RA.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Artrite
reumatoide</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2015) (SBR)
Posicionamento sobre o uso de tofacitinibe no algoritmo do Consenso
2012 da Sociedade Brasileira de Reumatologia para o tratamento da
artrite reumatoide</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.scielo.br/pdf/rbr/v55n6/0482-5004-rbr-55-06-0512.pdf">http://www.scielo.br/pdf/rbr/v55n6/0482-5004-rbr-55-06-0512.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2015) (ACR)
Diretriz para tratamento da artrite reumatoide</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/ACR%202015%20RA%20Guideline.pdf">http://www.rheumatology.org/Portals/0/Files/ACR%202015%20RA%20Guideline.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2013) (EULAR)
Recomendação EULAR para o manejo de artrite reumatoide com DMARDs
sintéticos e biológicos: atualização de 2013.</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/early/2013/10/23/annrheumdis-2013-204573.short?rss=1&amp;%3Bssource=mfr">http://ard.bmj.com/content/early/2013/10/23/annrheumdis-2013-204573.short?rss=1&amp;%3bssource=mfr</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2013) (SBR)
Diretrizes para o diagnóstico da artrite reumatoide</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.scielo.br/pdf/rbr/v53n2/v53n2a03.pdf">http://www.scielo.br/pdf/rbr/v53n2/v53n2a03.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2013) (SBR)
Diretrizes para o tratamento da artrite reumatoide</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.scielo.br/pdf/rbr/v53n2/v53n2a04.pdf">http://www.scielo.br/pdf/rbr/v53n2/v53n2a04.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2012) (ACR)
Atualização da recomendação de 2008 sobre o uso de DMARDs e
biológicos para tratamento da artrite reumatoide</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/2012%20Update%20of%20the%202008%20RA%20Recommendations.pdf">http://www.rheumatology.org/Portals/0/Files/2012%20Update%20of%20the%202008%20RA%20Recommendations.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2012) (ACR)
Avaliação da atividade da doença: recomendações para uso na
prática clínica</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/Rheumatoid%20Arthritis%20Disease%20Activity%20Measures.pdf">http://www.rheumatology.org/Portals/0/Files/Rheumatoid%20Arthritis%20Disease%20Activity%20Measures.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2012) (EULAR)
Recomendações sobre o uso de exames de imagem no manejo clínico de
pacientes com artrite reumatoide</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/early/2013/03/20/annrheumdis-2012-203158.abstract?papetoc">http://ard.bmj.com/content/early/2013/03/20/annrheumdis-2012-203158.abstract?papetoc</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2012) (SBR)
Consenso 2012 da Sociedade Brasileira de Reumatologia sobre vacinação
em pacientes com artrite reumatoide</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.scielo.br/pdf/rbr/v53n1/v53n1a02.pdf">http://www.scielo.br/pdf/rbr/v53n1/v53n1a02.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2012) (SBR)
Consenso 2012 da Sociedade Brasileira de Reumatologia sobre o manejo
de comorbidades em pacientes com artrite reumatoide.</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.scielo.br/pdf/rbr/v52n4/v52n4a02.pdf">http://www.scielo.br/pdf/rbr/v52n4/v52n4a02.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2011) (ACR/ EULAR)
Critérios de remissão</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/2011%20RA%20Remission%20Criteria_Complete%20Article_REMISSION.pdf">http://www.rheumatology.org/Portals/0/Files/2011%20RA%20Remission%20Criteria_Complete%20Article_REMISSION.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2009) (EULAR)
Recomendações EULAR para o manejo de artrite reumatoide com DMARDs
sintéticos e biológicos</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/early/2010/05/04/ard.2009.126532.abstract">http://ard.bmj.com/content/early/2010/05/04/ard.2009.126532.abstract</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2008) (ACR)
Recomendação para uso de DMARDs biológicos e não-biológicos na
artrite reumatoide</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/2008%20RA%20Recommendations.pdf">http://www.rheumatology.org/Portals/0/Files/2008%20RA%20Recommendations.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Autoinflamatórias,
síndromes</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2016) (SBR)
Diretrizes de conduta e tratamento de síndromes febris periódicas
associadas a febre familiar do Mediterrâneo</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.scielo.br/pdf/rbr/v56n1/0482-5004-rbr-56-01-0037.pdf">http://www.scielo.br/pdf/rbr/v56n1/0482-5004-rbr-56-01-0037.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2016) (SBR)
Diretrizes de conduta e tratamento de síndromes febris periódicas
associadas à criopirina (criopirinopatias – CAPS)</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.scielo.br/pdf/rbr/v56n1/0482-5004-rbr-56-01-0044.pdf">http://www.scielo.br/pdf/rbr/v56n1/0482-5004-rbr-56-01-0044.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2016) (SBR)
Diretrizes de conduta e tratamento de síndromes febris periódicas:
síndrome de febre periódica, estomatite aftosa, faringite e adenite</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.scielo.br/pdf/rbr/v56n1/0482-5004-rbr-56-01-0052.pdf">http://www.scielo.br/pdf/rbr/v56n1/0482-5004-rbr-56-01-0052.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2015) (EULAR)
Recomendações para o manejo de febre familiar do mediterrâneo. 
</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/early/2016/01/22/annrheumdis-2015-208690?papetoc">http://ard.bmj.com/content/early/2016/01/22/annrheumdis-2015-208690?papetoc</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Behçet, Doença
de</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2008) (EULAR)
Recomendações EULAR para manejo da doença de Behçet</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/67/12/1656.abstract">http://ard.bmj.com/content/67/12/1656.abstract</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Coluna Vertebral</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2008) (SBR) Coluna
Vertebral: Cirurgia com Fixação Dinâmica Posterior (Projeto
Diretrizes - AMB e CFM)</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.reumatologia.com.br/publicacoes/consensosDiretrizes/02-Coluna_Vertebral2008.pdf">http://www.reumatologia.com.br/publicacoes/consensosDiretrizes/02-Coluna_Vertebral2008.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2008) (SBR)
Diagnóstico e tratamento das Lombalgias e Lombociatalgias (Projeto
Diretrizes - AMB e CFM)</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.reumatologia.com.br/publicacoes/consensosDiretrizes/DiretrizesLombalgiaseLombociatalgias-Atualizacao2008.pdf">http://www.reumatologia.com.br/publicacoes/consensosDiretrizes/DiretrizesLombalgiaseLombociatalgias-Atualizacao2008.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Diversos (Outros)</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2016) (EULAR)
Considerações EULAR sobre uso de drogas antirreumáticas antes e
durante a gravidez e a lactação</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/early/2016/02/17/annrheumdis-2015-208840.full">http://ard.bmj.com/content/early/2016/02/17/annrheumdis-2015-208840.full</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2015) (EULAR)
Recomendações para educação de pacientes com artrite inflamatória</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/early/2015/03/03/annrheumdis-2014-206807.abstract">http://ard.bmj.com/content/early/2015/03/03/annrheumdis-2014-206807.abstract</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2015) (SBR)
Recomendações da Sociedade Brasileira de Reumatologia sobre
diagnóstico e tratamento das parasitoses intestinais em pacientes
com doenças reumáticas autoimunes</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.scielo.br/pdf/rbr/v55n4/0482-5004-rbr-55-04-0368.pdf">http://www.scielo.br/pdf/rbr/v55n4/0482-5004-rbr-55-04-0368.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2014) (SBR) IV
Consenso Brasileiro para pesquisa de autoanticorpos em células HEp-2
(FAN)</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.scielo.br/pdf/rbr/v54n1/0482-5004-rbr-54-01-0044.pdf">http://www.scielo.br/pdf/rbr/v54n1/0482-5004-rbr-54-01-0044.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2013) (EULAR)
Recomendação baseada em evidência e em consenso sobre terapia com
dose média e alta de glicocorticoides nas doenças reumáticas</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/early/2013/07/18/annrheumdis-2013-203249.abstract?papetoc">http://ard.bmj.com/content/early/2013/07/18/annrheumdis-2013-203249.abstract?papetoc</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2011) (EULAR)
Recomendações EULAR quanto ao papel da enfermagem no manejo da
artrite inflamatória crônica</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/early/2011/10/28/annrheumdis-2011-200185.abstract?papetoc">http://ard.bmj.com/content/early/2011/10/28/annrheumdis-2011-200185.abstract?papetoc</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2011) (EULAR)
Recomendações para a vacinação de pacientes adultos com doenças
reumatológicas autoimunes</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/70/3/414.abstract">http://ard.bmj.com/content/70/3/414.abstract</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2011) (EULAR)
Recomendações para a vacinação de pacientes pediátricos com
doenças reumatológicas autoimunes</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/early/2011/08/03/ard.2011.150193.abstract?papetoc">http://ard.bmj.com/content/early/2011/08/03/ard.2011.150193.abstract?papetoc</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2010) (EULAR)
Considerações sobre criação, análise e descrição de registros
sobre segurança de medicamentos biológicos na reumatologia</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/69/9/1596.abstract?sid=c7c52284-ef61-4409-b706-af19d71d4296">http://ard.bmj.com/content/69/9/1596.abstract?sid=c7c52284-ef61-4409-b706-af19d71d4296</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2010) (EULAR)
Recomendações baseadas em evidências sobre manejo de risco
cardiovascular em artrites inflamatórias</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/69/2/325.abstract">http://ard.bmj.com/content/69/2/325.abstract</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2009) (EULAR)
Monitorização de eventos adversos de glicocorticoides em dose
baixa: recomendações EULAR para ensaios clínicos e para a prática
clínica</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/early/2010/08/05/ard.2009.124958.abstract">http://ard.bmj.com/content/early/2010/08/05/ard.2009.124958.abstract</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2008) (EULAR)
Recomendações EULAR/EFORT para diagnóstico e manejo inicial de
pacientes com edema agudo ou de início recente nos joelhos</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/early/2009/01/15/ard.2008.104406.abstract">http://ard.bmj.com/content/early/2009/01/15/ard.2008.104406.abstract</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2007) (EULAR)
Recomendações baseadas em evidências para uso de glicocorticoides
nas doenças reumáticas</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/66/12/1560.abstract">http://ard.bmj.com/content/66/12/1560.abstract</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2007) (EULAR)
Recomendações para manejo de artrite inicial 
</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/66/1/34.full?keytype=ref&amp;siteid=bmjjournals&amp;ijkey=gX5c.9%2FvOKyDk">http://ard.bmj.com/content/66/1/34.full?keytype=ref&amp;siteid=bmjjournals&amp;ijkey=gX5c.9%2FvOKyDk</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Esclerose
Sistêmica</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2013) (SBR)
Recomendações sobre diagnóstico e tratamento da esclerose
sistêmica</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.scielo.br/pdf/rbr/v53n3/v53n3a04.pdf">http://www.scielo.br/pdf/rbr/v53n3/v53n3a04.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2009) (EULAR)
Recomendações EULAR para tratamento de esclerose sistêmica</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/68/5/620">http://ard.bmj.com/content/68/5/620</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Espondiloartrites</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2015) (ACR)
Recomendação para tratamento de espondilite anquilosante e
espondiloartrite axial não radiográfica</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/Recommendations%20for%20the%20Treatment%20of%20Ankylosing%20Spondylitis.pdf">http://www.rheumatology.org/Portals/0/Files/Recommendations%20for%20the%20Treatment%20of%20Ankylosing%20Spondylitis.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2015) (EULAR)
Tratamento farmacológico da artrite psoriásica: uma revisão
sistemática da literatura para a atualização EULAR de 2015 sobre
manejo da artrite psoriásica.</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/early/2015/12/11/annrheumdis-2015-208466.abstract">http://ard.bmj.com/content/early/2015/12/11/annrheumdis-2015-208466.abstract</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2015) (EULAR)
Recomendações EULAR para o manejo da artite psoriásica:
atualização de 2015.</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/early/2015/12/07/annrheumdis-2015-208337.full">http://ard.bmj.com/content/early/2015/12/07/annrheumdis-2015-208337.full</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2015) (EULAR)
Recomendações EULAR para uso de métodos de imagem no diagnóstico
e manejo das espondiloartrites na prática clínica.</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/early/2015/04/02/annrheumdis-2014-206971.abstract">http://ard.bmj.com/content/early/2015/04/02/annrheumdis-2014-206971.abstract</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2013) (SBR)
Recomendações sobre diagnóstico e tratamento da artrite psoriásica</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.scielo.br/pdf/rbr/v53n3/v53n3a02.pdf">http://www.scielo.br/pdf/rbr/v53n3/v53n3a02.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2013) (SBR)
Recomendações sobre diagnóstico e tratamento da espondilite
anquilosante</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.scielo.br/pdf/rbr/v53n3/v53n3a03.pdf">http://www.scielo.br/pdf/rbr/v53n3/v53n3a03.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2012) (EULAR)
Recomendações EULAR para o manejo farmacológico de artrite
psoriásica</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/71/1/4.abstract?sid=c0f5cb74-52f3-45db-a7e2-743a3541b812">http://ard.bmj.com/content/71/1/4.abstract?sid=c0f5cb74-52f3-45db-a7e2-743a3541b812</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2011) (ASAS/EULAR)
Atualização da recomendação de 2010 quanto ao manejo da
espondilite anquilosante</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/70/6/896.abstract?etoc">http://ard.bmj.com/content/70/6/896.abstract?etoc</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2009) (ASAS) Livro
de mão para avaliação das espondiloartrites</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.asas-group.org/publications/ASAS-handbook.pdf">http://www.asas-group.org/publications/ASAS-handbook.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2007) (SBR)
Consenso Brasileiro de Espondiloartropatias: Espondilite Anquilosante
e Artrite Psoriásica, Diagnóstico e Tratamento – Primeira Revisão</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.reumatologia.com.br/publicacoes/consensosDiretrizes/Consenso_EA_APsoriasica_2007.pdf">http://www.reumatologia.com.br/publicacoes/consensosDiretrizes/Consenso_EA_APsoriasica_2007.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2006) (EULAR/ASAS)
Recomendações para o manejo de espondilite anquilosante</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/65/4/442.abstract">http://ard.bmj.com/content/65/4/442.abstract</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2004) (SBR) Outras
espondiloartropatias (Projeto Diretrizes - AMB e CFM)</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.reumatologia.com.br/publicacoes/consensosDiretrizes/Espondiloartropatias%20outras.pdf">http://www.reumatologia.com.br/publicacoes/consensosDiretrizes/Espondiloartropatias%20outras.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Febre Reumática</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2009) (SBC)
Diretrizes Brasileiras para o Diagnóstico, Tratamento e Prevenção
da Febre Reumática</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://publicacoes.cardiol.br/consenso/2009/diretriz_febrereumatica_93supl04.pdf">http://publicacoes.cardiol.br/consenso/2009/diretriz_febrereumatica_93supl04.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2002) (SBR) Febre
Reumática (Projeto Diretrizes - AMB e CFM) 
</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.reumatologia.com.br/publicacoes/consensosDiretrizes/Diretriz_Febre_Reumatica.pdf">http://www.reumatologia.com.br/publicacoes/consensosDiretrizes/Diretriz_Febre_Reumatica.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Fibromialgia</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2010) (SBR)
Consenso brasileiro do tratamento da fibromialgia</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.scielo.br/pdf/rbr/v50n1/v50n1a06.pdf">http://www.scielo.br/pdf/rbr/v50n1/v50n1a06.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2008) (EULAR)
Recomendações baseadas em evidências para o manejo de fibromialgia</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/67/4/536.short">http://ard.bmj.com/content/67/4/536.short</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2004) (SBR)
Fibromialgia (Projeto Diretrizes - AMB e CFM)</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.reumatologia.com.br/publicacoes/consensosDiretrizes/Fibromialgia.pdf">http://www.reumatologia.com.br/publicacoes/consensosDiretrizes/Fibromialgia.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Gota</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2012) (ACR)
Diretriz para tratamento da gota (parte 1). Tratamento farmacológico
e não farmacológico da hiperuricemia</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/ACR%20Guidelines%20for%20Management%20of%20Gout_Part%201.pdf">http://www.rheumatology.org/Portals/0/Files/ACR%20Guidelines%20for%20Management%20of%20Gout_Part%201.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2012) (ACR)
Diretriz para tratamento da gota (parte 2). Tratamento e profilaxia
da artrite gotosa aguda</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/ACR%20Guidelines%20for%20Management%20of%20Gout_Part%202.pdf">http://www.rheumatology.org/Portals/0/Files/ACR%20Guidelines%20for%20Management%20of%20Gout_Part%202.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2006) (EULAR)
Recomendações baseadas em evidências sobre gota. Parte 1:
diagnóstico. 
</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/65/10/1301.abstract">http://ard.bmj.com/content/65/10/1301.abstract</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2006) (EULAR)
Recomendações baseadas em evidências sobre gota. Parte 2: manejo.</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/65/10/1312.abstract">http://ard.bmj.com/content/65/10/1312.abstract</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Lupus </b>
</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2015) (SBR)
Consenso da Sociedade Brasileira de Reumatologia para o diagnóstico,
manejo e tratamento da nefrite lúpica. 
</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ac.els-cdn.com/S0482500414002307/1-s2.0-S0482500414002307-main.pdf?_tid=0d978924-f053-11e5-9a43-00000aacb35f&amp;acdnat=1458667700_66bf80fede0eef8568a63113c9203b5a">http://ac.els-cdn.com/S0482500414002307/1-s2.0-S0482500414002307-main.pdf?_tid=0d978924-f053-11e5-9a43-00000aacb35f&amp;acdnat=1458667700_66bf80fede0eef8568a63113c9203b5a</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2012) (ACR)
Diretriz para rastreio e tratamento da nefrite lúpica</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/ACR%20Guidelines%20for%20Screening,%20Treatment,%20and%20Management%20of%20Lupus%20Nephritis.pdf">http://www.rheumatology.org/Portals/0/Files/ACR%20Guidelines%20for%20Screening,%20Treatment,%20and%20Management%20of%20Lupus%20Nephritis.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2012) (EULAR)
Recomendações EULAR/ERA-EDTA para o manejo de nefrite lúpica
pediátrica e adulta</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/early/2012/07/30/annrheumdis-2012-201940.abstract?papetoc">http://ard.bmj.com/content/early/2012/07/30/annrheumdis-2012-201940.abstract?papetoc</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2010) (EULAR)
Recomendações EULAR para o manejo de manifestações
neuropsiquiátricas do lúpus eritematoso sistêmico</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/69/12/2074.abstract?sid=b92bceb8-02f6-49f1-b493-d453a0425bb2">http://ard.bmj.com/content/69/12/2074.abstract?sid=b92bceb8-02f6-49f1-b493-d453a0425bb2</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2007) (EULAR)
Recomendações para manejo de lúpus eritematoso sistêmico</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/cgi/gca?allch=&amp;SEARCHID=1&amp;FULLTEXT=eular+sle&amp;FIRSTINDEX=0&amp;hits=10&amp;RESULTFORMAT=&amp;gca=annrheumdis;ard.2007.070367v2&amp;allchb">http://ard.bmj.com/cgi/gca?allch=&amp;SEARCHID=1&amp;FULLTEXT=eular+sle&amp;FIRSTINDEX=0&amp;hits=10&amp;RESULTFORMAT=&amp;gca=annrheumdis;ard.2007.070367v2&amp;allchb</a>=</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2004) (SBR) Lúpus
Eritematoso Sistêmico: Tratamento do Acometimento Sistêmico
(Projeto Diretrizes - AMB e CFM)</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.reumatologia.com.br/publicacoes/consensosDiretrizes/Lupus_sistemico.pdf">http://www.reumatologia.com.br/publicacoes/consensosDiretrizes/Lupus_sistemico.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2004) (SBR) Lúpus
Eritematoso Sistêmico: Tratamento do Acometimento Cutâneo/Articular
(Projeto Diretrizes - AMB e CFM)</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.reumatologia.com.br/publicacoes/consensosDiretrizes/Lupus_cutaneo.pdf">http://www.reumatologia.com.br/publicacoes/consensosDiretrizes/Lupus_cutaneo.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Osteoartrite </b>
</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2013) (EULAR)
Recomendações EULAR para o manejo não farmacológico de
osteoartrite dos joelhos e dos quadris</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/early/2013/04/16/annrheumdis-2012-202745.abstract?papetoc">http://ard.bmj.com/content/early/2013/04/16/annrheumdis-2012-202745.abstract?papetoc</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2012) (ACR)
Recomendação para tratamento de osteoartrite das mãos, quadris e
joelhos</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/ACR%20Recommendations%20for%20the%20Use%20of%20Nonpharmacologic%20and%20Pharmacologic%20Therapies%20in%20OA%20of%20the%20Hand,%20Hip%20and%20Knee.pdf">http://www.rheumatology.org/Portals/0/Files/ACR%20Recommendations%20for%20the%20Use%20of%20Nonpharmacologic%20and%20Pharmacologic%20Therapies%20in%20OA%20of%20the%20Hand,%20Hip%20and%20Knee.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2009) (ACR)
Diretriz para tratamento não farmacológico de osteoartrite do
joelho e quadril</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/ACR%20OA%20Guidelines%20Non-pharmacological%20-%20Knee%20and%20Hip.pdf">http://www.rheumatology.org/Portals/0/Files/ACR%20OA%20Guidelines%20Non-pharmacological%20-%20Knee%20and%20Hip.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2009) (EULAR)
Recomendações baseadas em evidência para o diagnóstico de
osteoartrite do joelho</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/early/2009/09/17/ard.2009.113100.abstract">http://ard.bmj.com/content/early/2009/09/17/ard.2009.113100.abstract</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2009) (EULAR)
Recomendações baseadas em evidências para o diagnóstico de
osteoartrite das mãos</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/68/1/8.abstract">http://ard.bmj.com/content/68/1/8.abstract</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2005) (EULAR)
Recomendações baseadas em evidências para o manejo de osteoartrite
do quadril</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/64/5/669.full">http://ard.bmj.com/content/64/5/669.full</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2003) (SBR)
Osteoartrite (Artrose): Tratamento (Projeto Diretrizes - AMB e CFM)</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.reumatologia.com.br/publicacoes/consensosDiretrizes/Osteoartrose%20Tratamento.pdf">http://www.reumatologia.com.br/publicacoes/consensosDiretrizes/Osteoartrose%20Tratamento.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Osteoporose</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2011) (SBR)
Osteoporose: tratamento (Projeto Diretrizes - AMB e CFM)</p>
<p style="margin-bottom: 0cm; line-height: 100%">
<a href="http://www.projetodiretrizes.org.br/ans/diretrizes/osteoporose-tratamento.pdf">http://www.projetodiretrizes.org.br/ans/diretrizes/osteoporose-tratamento.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2008) (SBDens)
Posições oficiais 2008 da Sociedade Brasileira de Densitometria
Clínica</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.sbdens.org.br/arquivos//abem-pos-of-2009.pdf">http://www.sbdens.org.br/arquivos//abem-pos-of-2009.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2002) (SBR)
Consenso Brasileiro de Osteoporose.</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.osteoprotecao.com.br/pdf/consenso_brasileiro_osteoporose.pdf">http://www.osteoprotecao.com.br/pdf/consenso_brasileiro_osteoporose.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Osteoporose
induzida por corticoide</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2011) (SBR)
Osteoporose Induzida por Glicocorticoide: Prevenção e Tratamento
(Projeto Diretrizes - AMB e CFM)</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.scielo.br/pdf/rbr/v52n4/v52n4a09.pdf">http://www.scielo.br/pdf/rbr/v52n4/v52n4a09.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2010) (ACR)
Recomendação para prevenção e tratamento de osteoporose induzida
por corticoide</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/portals/0/files/ACR%202010%20Recommendations%20for%20the%20Prevention%20and%20Treatment%20of%20Glucocorticoid-Induced%20Osteoporosis.pdf">http://www.rheumatology.org/portals/0/files/ACR%202010%20Recommendations%20for%20the%20Prevention%20and%20Treatment%20of%20Glucocorticoid-Induced%20Osteoporosis.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2010) (ACR) Guia
clínico - Recomendação para prevenção e tratamento de
osteoporose induzida por corticoide (Resumo)</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/portals/0/files/Clinician%E2%80%99s%20Guide%20to%20the%20ACR%202010%20Recommendations%20for%20the%20Prevention%20and%20Treatment%20of%20Glucocorticoid-Induced%20Osteoporosis.pdf">http://www.rheumatology.org/portals/0/files/Clinician%E2%80%99s%20Guide%20to%20the%20ACR%202010%20Recommendations%20for%20the%20Prevention%20and%20Treatment%20of%20Glucocorticoid-Induced%20Osteoporosis.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Osteoporose
pós-menopausa</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2004) (SBR)
Osteoporose em Mulheres na Pós-Menopausa (Projeto Diretrizes - AMB e
CFM)</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.scielo.br/pdf/rbr/v44n6/06.pdf">http://www.scielo.br/pdf/rbr/v44n6/06.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Paget, Doença de
</b>
</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2004) (SBR) Doença
de Paget (Projeto Diretrizes - AMB e CFM)</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.reumatologia.com.br/index.asp?Perfil=&amp;Menu=Publicacoes&amp;Pagina=publicacoes/in_consensos_e_diretrizes_resultados.asp">http://www.reumatologia.com.br/index.asp?Perfil=&amp;Menu=Publicacoes&amp;Pagina=publicacoes/in_consensos_e_diretrizes_resultados.asp</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Polimialgia
reumática</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2015) (ACR)
Recomendação para manejo da polimialgia reumática</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/2015%20PMR%20guidelines.pdf">http://www.rheumatology.org/Portals/0/Files/2015%20PMR%20guidelines.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2003) (EULAR)
Criterios de resposta na polimialgia reumática</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/62/12/1189.full">http://ard.bmj.com/content/62/12/1189.full</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Pseudogota
(Doença por depósito de pirofosfato de cálcio)</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2011) (EULAR)
Recomendações sobre a doença por depósito de pirofosfato de
cálcio. Parte 1: terminologia e diagnóstico</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/70/4/563.abstract?sid=2d8a1a31-4e01-45a0-9188-d4094f6afc69">http://ard.bmj.com/content/70/4/563.abstract?sid=2d8a1a31-4e01-45a0-9188-d4094f6afc69</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">(2011) (EULAR)
Recomendações sobre a doença por depósito de pirofosfato de
cálcio. Parte 2: manejo.</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://ard.bmj.com/content/70/4/571.abstract?sid=43e9b750-60bf-4a8a-9651-58ccc419078b">http://ard.bmj.com/content/70/4/571.abstract?sid=43e9b750-60bf-4a8a-9651-58ccc419078b</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Pré-operatorio</b></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Síndrome
Antifosfolipídio</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2013) (SBR)
Diretrizes para o tratamento da síndrome do anticorpo
antifosfolipídeo</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.scielo.br/pdf/rbr/v53n2/v53n2a05.pdf">http://www.scielo.br/pdf/rbr/v53n2/v53n2a05.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Síndrome de
Sjögren</b></p>
<p style="margin-bottom: 0cm; line-height: 100%">(2015) (SBR)
Recomendações para o tratamento da síndrome de Sjögren</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.scielo.br/pdf/rbr/v55n5/0482-5004-rbr-55-05-0446.pdf">http://www.scielo.br/pdf/rbr/v55n5/0482-5004-rbr-55-05-0446.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>Vasculites</b></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0.35cm; line-height: 115%"><br/>
<br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%; page-break-before: always">
<b>MÉTRICAS</b></p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><b>#
Artrite Reumatoide</b></p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><b>DAS
28</b> = Disease Activity Score. Calculador:</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.das-score.nl/das28/en/">http://www.das-score.nl/das28/en/</a></p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">DAS28
– Artigo original</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/Modified%20Disease%20Activity%20Score_28.pdf">http://www.rheumatology.org/Portals/0/Files/Modified%20Disease%20Activity%20Score_28.pdf</a></p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	</p>
<p align="justify" style="text-indent: 1.25cm; margin-bottom: 0cm; line-height: 100%">
Escore de atividade da doença (artrite reumatoide). Avalia 28
articulações (IFPs, MCFs, punhos, cotovelos, ombros e joelhos), VHS
ou PCR, e percepção global da doença pelo paciente (EVA de 0-100).
</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	No
site oficial (link acima), há também versões sem a escala visual
analógica (EVA) e a versão original com 44 articulações (DAS44 ou
simplesmente DAS). 
</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	-
Interpretação:</p>
<p align="justify" style="text-indent: 1.25cm; margin-bottom: 0cm; line-height: 100%">
&lt;2,6: remissão</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	2,6
a 3,2: atividade baixa</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	&gt;3,2
a 5,1: atividade moderada</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	&gt;5,1:
atividade alta</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	Diminuição
de 0,6: resposta moderada. 
</p>
<p align="justify" style="text-indent: 1.25cm; margin-bottom: 0cm; line-height: 100%">
Diminuição de 1,2: resposta importante.  
</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><b>SDAI
</b>= Simplified Disease Activity Index</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/SDAI%20Form.pdf">http://www.rheumatology.org/Portals/0/Files/SDAI%20Form.pdf</a></p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	É
o índice simplificado de atividade da doença (artrite reumatoide).
Não necessita de calculadora (ao contrário do DAS).</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	-
Como calcular: é a soma linear dos seguintes parâmetros:</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	28
articulações dolorosas (cada uma pontua 1 ponto)</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	28
articulações edemaciadas (cada uma pontua 1 ponto)</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	EVA
doença – paciente (0-10)</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	EVA
doença – médico (0-10)</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	PCR
(em mg/dL) – de zero a 10.</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	</p>
<p align="justify" style="text-indent: 1.25cm; margin-bottom: 0cm; line-height: 100%">
Total máximo: 86 pontos. Como interpretar:</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	&lt;=
3,3: remissão</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	&gt;
3,3 a &lt;=11: atividade baixa</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	&gt;
11 a &lt;=26: atividade moderada</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	&gt;26:
atividade alta</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	Melhora
pequena: &gt;=50%</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	M.
moderada: &gt;=70%</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	M.
importante: &gt;=85%</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><b>CDAI</b> =
Clinical Disease Activity Index</p>
<p style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.rheumatology.org/Portals/0/Files/CDAI%20Form.pdf">http://www.rheumatology.org/Portals/0/Files/CDAI%20Form.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">	É o índice de
atividade clínica da doença (artrite reumatoide). É análogo ao
SDAI, contudo sem o PCR. 
</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	-
Como calcular: é a soma linear dos seguintes parâmetros:</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	28
articulações dolorosas (cada uma pontua 1 ponto)</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	28
articulações edemaciadas (cada uma pontua 1 ponto)</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	EVA
doença – paciente (0-10)</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	EVA
doença – médico (0-10)</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p align="justify" style="text-indent: 1.25cm; margin-bottom: 0cm; line-height: 100%">
Total máximo: 76 pontos. Como interpretar:</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	&lt;=
2,8: remissão</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	&gt;
2,8 a &lt;=10: atividade baixa</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	&gt;
10 a &lt;=22: atividade moderada</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	&gt;22:
atividade alta</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><b>#
Espondiloartropatias</b></p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><b>ASDAS</b>
= Ankylosing Spondylitis Disease Activity Score</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.asas-group.org/clinical-instruments/asdas_calculator/asdas.html">http://www.asas-group.org/clinical-instruments/asdas_calculator/asdas.html</a></p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	</p>
<p align="justify" style="text-indent: 1.25cm; margin-bottom: 0cm; line-height: 100%">
Escore de atividade da Espondilite Anquilosante</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	-
Interpretação:</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	&lt;1,3:
doença inativa. 
</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	&lt;2,1:
atividade moderada</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	2,2
a 3,5: atividade alta</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	&gt;3,5:
atividade muito alta</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	Uma
mudança &gt;= 1,1 é clinicamente significante.</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	Uma
mudança &gt;= 2,0 é uma mudança muito significativa</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><span lang="en-US"><b>BASDAI</b></span><span lang="en-US">
= Bath Ankylosing Spondylitis Disease Activity Index</span></p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><a href="http://basdai.com/select.htm">http://basdai.com/select.htm</a>
(inglês)</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.asas-group.org./clinical-instruments/clinical_instruments/asas_basdai_pt.pdf">http://www.asas-group.org./clinical-instruments/clinical_instruments/asas_basdai_pt.pdf</a>
(português - PT)</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	</p>
<p align="justify" style="text-indent: 1.25cm; margin-bottom: 0cm; line-height: 100%">
Índice de atividade de Bath para a espondilite anquilosante</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	Escore
de zero a 10. Se &gt;=4: indica atividade da doença.</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	Uma
mudança maior ou igual a 2 pontos após intervenção terapêutica é
considerada significativa.</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	Como
calcular: são 6 perguntas. Obter a média das perguntas 5 e 6
(gravidade e duração da rigidez matinal). Esta média é somada ao
resultado das perguntas 1-4 e obtém-se uma média de 5 valores, o
que resulta em um valor de 0 a 10.</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><span lang="en-US"><b>BASFI</b></span><span lang="en-US">
= Bath Ankylosing Spondylitis Functional Index</span></p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><a href="http://basdai.com/select.htm">http://basdai.com/select.htm</a>
(inglês)</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.asas-group.org./clinical-instruments/clinical_instruments/asas_basfi_pt.pdf">http://www.asas-group.org./clinical-instruments/clinical_instruments/asas_basfi_pt.pdf</a>
(português-PT)</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	</p>
<p align="justify" style="text-indent: 1.25cm; margin-bottom: 0cm; line-height: 100%">
Índice functional de Bath para a espondilite anquilosante</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	Como
calcular: fazer uma média dos valores obtidos nas 10 perguntas quem
compõem o índice. 
</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><span lang="en-US"><b>BASMI</b></span><span lang="en-US">
= Bath Ankylosing Spondylitis Metrology Index</span></p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%"><a href="http://www.asas-group.org./clinical-instruments/clinical_instruments/asas_basmi_pt.pdf">http://www.asas-group.org./clinical-instruments/clinical_instruments/asas_basmi_pt.pdf</a>
(português - PT)</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	</p>
<p align="justify" style="text-indent: 1.25cm; margin-bottom: 0cm; line-height: 100%">
Índice métrico de Bath para a espondilite anquilosante</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	Como
calcular: cada alteração pode pontuar de zero a 2, e como são 5
itens avaliados, o final é um escore de zero até 10. Quanto mais
alto o índice, mais grave o acometimento do paciente. 
</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	Há
também uma versão (BASMI 10) que, ao invés de cada item pontuar de
zero a 2, cada item pontua de zero a 10. Após, o resultado total é
dividido por 10 e o resultado final fica também de zero a 10. <span lang="en-US">(link
pdf da NASS – National Ankylosing Spondylitis Society – UK)</span></p>
<p lang="en-US" style="margin-bottom: 0.35cm; line-height: 115%"><br/>
<br/>

</p>
<p lang="en-US" style="margin-bottom: 0.35cm; line-height: 115%"><br/>
<br/>

</p>
<p lang="en-US" style="margin-bottom: 0.35cm; line-height: 115%"><br/>
<br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%; page-break-before: always">
<span lang="en-US"><b># Lúpus</b></span></p>
<p lang="en-US" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><span lang="en-US"><b>SLEDAI
2K = </b></span><span lang="en-US">Systemic Lupus Erythematosus
Disease Activiy Index 2000</span></p>
<p style="margin-bottom: 0cm; line-height: 100%">Artigo original -
<a href="http://www.jrheum.org/content/29/2/288.long">http://www.jrheum.org/content/29/2/288.long</a></p>
<p style="margin-bottom: 0cm; line-height: 100%">SELENA – SLEDAI
<a href="http://www.nejm.org/doi/suppl/10.1056/NEJMoa051135/suppl_file/nejm_petri_2550sa1.pdf">http://www.nejm.org/doi/suppl/10.1056/NEJMoa051135/suppl_file/nejm_petri_2550sa1.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%">Calculadora -
<a href="https://www.qxmd.com/calculate/calculator_335/sledai-2k">https://www.qxmd.com/calculate/calculator_335/sledai-2k</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	O
índice de atividade do lúpus eritematoso sistêmico 2000
(SLEDAI-2K) é uma modificação do SLEDAI original que pontua também
as seguintes alterações crônicas (e não apenas agudas):
persistência de alopecia, úlceras orais e proteinúria. 
</p>
<p align="justify" style="text-indent: 1.25cm; margin-bottom: 0cm; line-height: 100%">
A atividade da doença é avaliada nos últimos 10 dias. O índice
varia de 0 a 105 pontos, e um valor maior ou igual a 6 indica uma
alteração clínica significativa suficiente para mudar o manejo.</p>
<p align="justify" style="text-indent: 1.25cm; margin-bottom: 0cm; line-height: 100%">
Os critérios de SELENA-SLEDAI de exacerbação leve/moderada ou
grave podem ser visualizados no link acima. 
</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">		</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><span lang="en-US"><b>SLICC/
ACR SDI</b></span><span lang="en-US"> (</span><span lang="en-US"><b>1997)
</b></span><span lang="en-US">– Systemic lupus international
collaborating clinics/ American College of Rheumatology damage index</span></p>
<p style="margin-bottom: 0cm; line-height: 100%">Artigo original -
<a href="http://www.rheumatology.org/Portals/0/Files/SLICC%20ACR%20Damage%20Index%201996.pdf">http://www.rheumatology.org/Portals/0/Files/SLICC%20ACR%20Damage%20Index%201996.pdf</a></p>
<p style="margin-bottom: 0cm; line-height: 100%">Calculadora -
<a href="http://www.qxmd.com/calculate/calculator_336/slicc-acr-damage-index">http://www.qxmd.com/calculate/calculator_336/slicc-acr-damage-index</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p align="justify" style="text-indent: 1.25cm; margin-bottom: 0cm; line-height: 100%">
O índice de dano crônico no lúpus eritematoso sistêmico pontua de
0 a 46, e inclui alterações que estejam presentes há pelo menos 6
meses ou que sejam irreversíveis. O índice é cumulativo e valores
mais altos estão associados a pior prognóstico e maior mortalidade.</p>
<p style="text-indent: 1.25cm; margin-bottom: 0cm; line-height: 100%">
<br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><span lang="en-US"><b>#
Osteoporose</b></span></p>
<p lang="en-US" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><span lang="en-US"><b>FRAX
</b></span><span lang="en-US">– WHO Fracture Risk Assessment Tool </span>
</p>
<p style="margin-bottom: 0cm; line-height: 100%">Calculadora -
<a href="https://www.shef.ac.uk/FRAX/tool.aspx?country=55">https://www.shef.ac.uk/FRAX/tool.aspx?country=55</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p align="justify" style="margin-bottom: 0cm; line-height: 100%">	O
FRAX avalia o risco em 10 anos de fraturas osteoporóticas do quadril
ou em geral (quadril, coluna, úmero proximal ou antebraço) em
pacientes virgens de tratamento. Os pacientes são considerados de
alto risco para fraturas caso tenham uma densitometria com osteopenia
e um risco em 10 anos de fratura do quadril &gt;=3% ou em geral
&gt;=20%.  
</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><span lang="en-US"><b>#
Síndrome Sjögren</b></span></p>
<p lang="en-US" style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%"><span lang="en-US"><b>ESSDAI
</b></span><span lang="en-US">– EULAR Sjögren’s Syndrome Disease
Activity Index </span>
</p>
<p style="margin-bottom: 0cm; line-height: 100%">Artigo original -
<a href="http://ard.bmj.com/content/early/2009/06/28/ard.2009.110619.abstract">http://ard.bmj.com/content/early/2009/06/28/ard.2009.110619.abstract</a></p>
<p style="margin-bottom: 0cm; line-height: 100%"><br/>

</p>
<p style="margin-bottom: 0cm; line-height: 100%">	Índice EULAR de
atividade da Síndrome de Sjögren.</p>